在本期《骨髓移植》特刊中，研究人员报告了 IDH1 [1]、IDH2 [2] 和 FLT3-TKD [3] 可测量残留病 (MRD) 造血细胞移植前 (HCT) 对预测急性骨髓移植复发的影响。接受同种异体 HCT 的成人骨髓性白血病 (AML)。这些回顾性队列的患者群体（反映了临床移植实践模式和研究生物库参与情况）在每项研究中均为 84-86% 的非西班牙裔白人 (NHW)。在这篇评论中，我们探讨了获得 HCT 和 HCT 相关研究的种族和民族差异的影响，并鉴于该领域对 HCT 结果的新兴影响，提出了促进精准医学代表性的策略。© 2024。作者（ s)，经 Springer Nature Limited 独家许可。

In this special issue of Bone Marrow Transplantation, investigators report the impact of IDH1 [1], IDH2 [2], and FLT3-TKD [3] measurable residual disease (MRD) pre-hematopoietic cell transplantation (HCT) in predicting relapse of acute myeloid leukemia (AML) in adults receiving allogeneic HCT. The patient population for these retrospective cohorts, reflecting clinical transplant practice patterns and research biobank participation, was 84-86% non-Hispanic White (NHW) in each study. In this commentary, we explore the implications of racial and ethnic disparities in access to both HCT and HCT-related research and propose strategies to promote representation in precision medicine, given the emerging impact of the field on HCT outcomes.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.